-
EP4167994
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4167994
| EP4167994 - 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 24.03.2023 Database last updated on 24.07.2024 | |
| Former | The international publication has been made Status updated on 24.12.2021 | Most recent event Tooltip | 25.06.2024 | Supplementary search report | published on 24.07.2024 [2024/30] | Applicant(s) | For all designated states Merck Sharp & Dohme LLC 126 East Lincoln Avenue Rahway, New Jersey 07065 / US | [2023/17] | Inventor(s) | 01 /
ARASAPPAN, Ashok Kenilworth, New Jersey 07033 / US | 02 /
BELL, Ian, M. West Point, Pennsylvania 19486 / US | 03 /
BUNGARD, Christopher James West Point, Pennsylvania 19486 / US | 04 /
BURGEY, Christopher, S. West Point, Pennsylvania 19486 / US | 05 /
COX, Jason, M. Flemington, New Jersey 08822 / US | 06 /
GUIADEEN, Deodial Guy Kenilworth, New Jersey 07033 / US | 07 /
KELLY, Michael, J., III West Point, Pennsylvania 19486 / US | 08 /
LAYTON, Mark, E. West Point, Pennsylvania 19486 / US | 09 /
LIU, Hong Kenilworth, New Jersey 07033 / US | 10 /
LIU, Jian Edison, New Jersey 08820 / US | 11 /
OLSEN, James, T. Waco, Texas 76706 / US | 12 /
PERKINS, James, J. West Point, Pennsylvania 19486 / US | 13 /
SCHUBERT, Jeffrey, W. West Point, Pennsylvania 19486 / US | 14 /
SHAH, Akshay, A. West Point, Pennsylvania 19486 / US | 15 /
STACHEL, Shawn, J. West Point, Pennsylvania 19486 / US | 16 /
VANHEYST, Michael, D. Harleysville, Pennsylvania 19438 / US | 17 /
WU, Zhe Blue Bell, Pennsylvania 19422 / US | [2023/17] | Representative(s) | Merck Sharp & Dohme LLC 120 Moorgate London EC2M 6UR / GB | [2023/17] | Application number, filing date | 21827155.9 | 14.06.2021 | [2023/17] | WO2021US37157 | Priority number, date | US202063040463P | 17.06.2020 Original published format: US 202063040463 P | [2023/17] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021257418 | Date: | 23.12.2021 | Language: | EN | [2021/51] | Type: | A1 Application with search report | No.: | EP4167994 | Date: | 26.04.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 23.12.2021 takes the place of the publication of the European patent application. | [2023/17] | Search report(s) | International search report - published on: | US | 23.12.2021 | (Supplementary) European search report - dispatched on: | EP | 24.06.2024 | Classification | IPC: | A61K31/4045, A61K31/4155, A61K31/4178 | [2023/17] | CPC: |
C07D413/12 (EP,KR,US);
A61K31/421 (KR);
A61K31/427 (KR);
A61K31/4439 (KR);
A61K31/506 (KR);
A61P29/00 (EP,KR);
C07D263/20 (EP);
C07D263/24 (KR,US);
C07D417/12 (EP,KR,US);
C07D417/14 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/17] | Extension states | BA | 17.01.2023 | ME | 17.01.2023 | Validation states | MA | 17.01.2023 | MD | 17.01.2023 | TN | 17.01.2023 | Title | German: | 2-OXO-OXAZOLIDIN-5-CARBOXAMIDE ALS NAV1.8-INHIBITOREN | [2023/17] | English: | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS | [2023/17] | French: | 2-OXOIMIDAZOLIDINE-5-CARBOXAMIDES UTILES EN TANT QU'INHIBITEURS DE NAV1.8 | [2023/17] | Entry into regional phase | 17.01.2023 | National basic fee paid | 17.01.2023 | Search fee paid | 17.01.2023 | Designation fee(s) paid | 17.01.2023 | Examination fee paid | Examination procedure | 16.01.2023 | Amendment by applicant (claims and/or description) | 17.01.2023 | Examination requested [2023/17] | Fees paid | Renewal fee | 31.03.2023 | Renewal fee patent year 03 | 31.03.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO0144230 (AMGEN INC [US]); | [I]WO2012177893 (AMGEN INC [US], et al); |